How Often Can You Get an Allergy Shot? Immunotherapy vs. Steroid Shots

Steroid allergy shots (such as triamcinolone/Kenalog) and immunotherapy allergy shots (SCIT) are fundamentally different treatments that share a confusing informal name. A steroid allergy shot is a corticosteroid injection that suppresses the immune system's allergic response for 2-6 weeks. It provides no disease modification — symptoms return to baseline once the drug clears. It is limited to 3-4 injections per year due to cumulative side effects including bone density loss, adrenal suppression, and elevated blood glucose. An immunotherapy allergy shot (SCIT) is an injection of allergen extract in gradually increasing doses that trains the immune system to tolerate the allergen. It produces lasting disease modification, has no annual injection limit during treatment, and is given weekly to monthly for 3-5 years.

Steroid allergy shots such as triamcinolone acetonide (Kenalog) are recommended at a maximum frequency of 3-4 injections per year per AAAAI guidance. Each injection provides approximately 2-6 weeks of symptom relief before the corticosteroid clears from the body. Exceeding the 3-4 annual limit substantially increases cumulative risks: bone density loss of approximately 1-2% per year with quarterly injections, suppression of the adrenal gland's natural cortisol production, elevated blood glucose particularly in diabetic patients, skin atrophy at the injection site, and increased risk of posterior subcapsular cataracts. Oral corticosteroid bursts (prednisone for 5-7 days) are often recommended as an alternative for acute allergy flares to avoid depot injection risks.

Yes — steroid shots and immunotherapy allergy shots can be used simultaneously, and this combination is sometimes appropriate during the build-up phase of SCIT when patients are still experiencing significant symptoms before the immunotherapy takes effect. However, this should be coordinated with your allergist. Steroid shots do not interfere with the immunological mechanism of SCIT, but they should not be seen as a substitute for continuing immunotherapy. The purpose of combining them is temporary symptom management during the months before SCIT reaches full clinical effect. Long-term reliance on repeated steroid shots in lieu of completing SCIT is medically discouraged due to the cumulative risks of corticosteroid use.

Getting steroid allergy shots more frequently than 3-4 times per year substantially increases cumulative risk. AAAAI guidance identifies the key concerns: bone density loss of approximately 1-2% per year with quarterly injections — a risk that accumulates and is not reversible; adrenal suppression where the adrenal glands reduce natural cortisol production in response to exogenous corticosteroid, which can cause fatigue, weakness, and adrenal crisis under physiological stress; elevated blood glucose particularly dangerous for diabetic patients; skin atrophy and subcutaneous fat loss at the injection site with repeated use; and increased posterior subcapsular cataract risk. These risks increase with dose, frequency, and duration of use — which is why the 3-4/year maximum is a safety guardrail, not an arbitrary limit.

No — immunotherapy allergy shots (SCIT) have no annual injection limit. They are designed for long-term weekly-to-monthly use over 3-5 years, with the total annual injection count varying from approximately 13 injections per year during monthly maintenance to 26 per year during biweekly maintenance. Allergen extracts used in SCIT do not accumulate in the body and cause no organ toxicity from repeated use. The safety constraint on SCIT is the per-injection systemic reaction rate (0.1-0.2% per injection in conventional protocols) — not cumulative organ effects. The 30-minute post-injection observation requirement at every visit is the primary safety protocol, ensuring that any systemic reaction can be promptly treated with epinephrine.

Steroid shots and immunotherapy address allergy symptoms through opposite mechanisms with very different long-term profiles. Steroid shots suppress the immune response temporarily — providing 2-6 weeks of relief without any immune retraining. Immunotherapy shots gradually retrain the immune system over 3-5 years, producing lasting disease modification that persists 3-12 years after treatment ends (Durham et al., NEJM 1999). For short-term acute relief — particularly during peak allergy season before immunotherapy takes effect — steroid shots can be appropriate. For patients wanting durable, disease-modifying treatment that eventually ends and leaves lasting benefit, immunotherapy is the evidence-based choice. Indefinite reliance on steroid shots for allergy management is not recommended due to cumulative corticosteroid side effects.